slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 223,711-223,740
Pages 10,126
Rows per page 30
Component
223,711-223,740 of 303,780
25
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red/grey).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
26
The slide uses a red dashed box to highlight the key clinical data rows (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
27
The slide uses a side-by-side comparison of two disease indications, showing clinical results, relevant competitor benchmarks, and market size.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
28
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
29
The table displays clinical trial data for NXC-201, specifically focusing on safety profiles and management interventions.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
32
The slide features a scientific illustration of cellular structures, likely representing the drug's mechanism of action or target environment.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
34
Slide contains three distinct charts comparing IMX-110 against standard of care and other combinations in mouse models.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
35
Includes a process diagram illustrating the mechanism of action of IMX-110 in turning cold tumors hot.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
36
Includes Kaplan-Meier survival curves and bioluminescence imaging of tumor activity.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
37
Immix Biopharma | Investor Presentation Deck | 57 slidesImmix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
38
Includes waterfall charts and longitudinal patient response plots. Source note provided at bottom.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
39
The slide uses a bubble chart to map clinical trials and a table to summarize drug performance metrics, highlighting low efficacy and high toxicity.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
40
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a small sample size (n=4).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
41
The slide uses a process flow diagram to show trial progression for two distinct treatment arms.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
42
Immix Biopharma | Investor Presentation Deck | 57 slidesImmix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
45
Includes technical diagrams of the drug delivery mechanism and comparative survival data.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
46
Includes two sets of charts: tumor volume over time and survival curves. References specific dosing schedules and study parameters.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
47
Includes detailed scientific diagrams of the drug mechanism and clinical trial results.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
48
Immix Biopharma | Investor Presentation Deck | 57 slidesImmix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
49
The slide is divided into two sections: ImmixBio Clinical Advisory Board (top) and Select Nexcella Scientific Advisory Board (bottom).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
50
Immix Biopharma | Investor Presentation Deck | 57 slidesImmix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
51
The slide is organized into two rows, one for each company's board members, featuring headshots, names, titles, and company logos.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
52
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
53
Immix Biopharma | Investor Presentation Deck | 57 slidesImmix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
54
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
55
The slide uses a combination of expert testimonials and a comparative clinical trial table to validate the outpatient administration model.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
56
The slide uses a bar chart to contrast the combined annual sales of two sets of oncology drugs.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
57
The slide compares efficacy benchmarks of established competitors (AbbVie, J&J, Takeda) to set a baseline for the IMX-120 opportunity.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
02
Independent Bank Corp | Results Presentation Deck | 27 slidesIndependent Bank Corp | Results Presentation Deck | 27 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Attention1 hit